SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
SOLIGENIX, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.34−0.01 (-2.66%)
Close on Oct 19, 2026
- Market cap
- $5.48M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.3063 (−79.17%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $5.48M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.83
- Dividend yield
- –
- Free cash flow yield
- -187.36%
Fundamentals
- Net income
- -$10.24M
- EPS, diluted
- -$2.14
- Free cash flow
- -$10.27M
- Book value per share
- $0.42
- Diluted shares
- 16M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$11.04M
Net income
-$10.24M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months